These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 51155)

  • 21. Editorial comment.
    Montie JE
    Urology; 2009 May; 73(5):939; author reply 939. PubMed ID: 19394485
    [No Abstract]   [Full Text] [Related]  

  • 22. [Pathogenesis of prostatic carcinoma. II. The relation between precancerous lesions and carcinoma of the prostate].
    Wu RL
    Zhonghua Zhong Liu Za Zhi; 1984 May; 6(3):189-91. PubMed ID: 6210185
    [No Abstract]   [Full Text] [Related]  

  • 23. [Incidental carcinoma of the prostate].
    Vecchioli Scaldazza C; Garritano A; Rossi G; Albini C
    Arch Ital Urol Nefrol Androl; 1989 Mar; 61(1):37-42. PubMed ID: 2469128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. When to investigate benign prostatic hyperplasia.
    Thomas D
    Practitioner; 1997 Jul; 241(1576):408-13. PubMed ID: 9425714
    [No Abstract]   [Full Text] [Related]  

  • 25. [Incidental carcinoma of the prostate. Study of 683 patients operated upon for benign prostatic hypertrophy].
    Vecchioli Scaldazza C
    Minerva Urol Nefrol; 1992; 44(2):109-12. PubMed ID: 1384152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Propionibacterium acnes infection associated with cancerous prostate hypertrophy.
    Olender A; Radej S; Płaza P; Bar K; Maciejewski R
    Pol Arch Med Wewn; 2016 Sep; 126(9):697-699. PubMed ID: 27629109
    [No Abstract]   [Full Text] [Related]  

  • 27. Prostate cancer. Epidemiology.
    Alderson MR
    Recent Results Cancer Res; 1981; 78():1-19. PubMed ID: 6168010
    [No Abstract]   [Full Text] [Related]  

  • 28. [Cancer of the prostate].
    Bouffioux C
    Acta Urol Belg; 1979 Apr; 47(2):189-470. PubMed ID: 90455
    [No Abstract]   [Full Text] [Related]  

  • 29. [Dual 5-alpha reductase inhibitors in BPH (benign prostatic hyperplasia). Already after 1 month prostate shrinks].
    MMW Fortschr Med; 2003 Feb; 145(9):54. PubMed ID: 12666533
    [No Abstract]   [Full Text] [Related]  

  • 30. Lower urinary tract symptoms, benign prostatic hyperplasia, and prostate cancer: seek and ye shall find.
    Silberstein JL; Eastham JA
    Eur Urol; 2013 Jun; 63(6):1028-9; discussion 1030. PubMed ID: 23375431
    [No Abstract]   [Full Text] [Related]  

  • 31. [Occult cancer in patients with symptomatic benign prostatic hyperplasia].
    Rodríguez Duarte C; Aguillón J; Rodríguez H
    Arch Esp Urol; 1991 May; 44(4):411-4. PubMed ID: 1712190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
    Kristal AR; Arnold KB; Schenk JM; Neuhouser ML; Weiss N; Goodman P; Antvelink CM; Penson DF; Thompson IM
    J Urol; 2007 Apr; 177(4):1395-400; quiz 1591. PubMed ID: 17382740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia.
    Bechis SK; Otsetov AG; Ge R; Wang Z; Vangel MG; Wu CL; Tabatabaei S; Olumi AF
    J Urol; 2015 Oct; 194(4):1031-7. PubMed ID: 25916673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathogenesis of prostatic hyperplasia and neoplasia.
    Roberts HJ
    Geriatrics; 1967 Dec; 22(12):85-92. PubMed ID: 4168607
    [No Abstract]   [Full Text] [Related]  

  • 35. [Sexual problems in patients with prostate cancer and those with benign prostatic hypertrophy].
    Danilin JE; Marilov VV; Brukhin AE
    Rev Med Suisse; 2011 Mar; 7(287):648, 650-2. PubMed ID: 21542379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Urination disorders in middle-aged men. Adenoma and carcinoma of the prostate].
    Nagel R
    Med Monatsschr; 1968 Apr; 22(4):153-9. PubMed ID: 4177968
    [No Abstract]   [Full Text] [Related]  

  • 37. Hyperplasia, atypism, and carcinoma in situ in prostatic periurethral glands.
    Ullmann AS; Ross OA
    Am J Clin Pathol; 1967 Apr; 47(4):497-504. PubMed ID: 4164333
    [No Abstract]   [Full Text] [Related]  

  • 38. Re: Athanassios Oeconomou, Helmut Madersbacher, Gustav Kiss, Thomas J. Berger, Michael Melekos and Peter Rehder. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? a review of the literature. Eur Urol 2008;54:765-77.
    Brisinda G; Vanella S; Maria G
    Eur Urol; 2009 Jul; 56(1):e10-1; author reply e12-3. PubMed ID: 19375845
    [No Abstract]   [Full Text] [Related]  

  • 39. [Epidemiological aspects of benign prostatic hypertrophy].
    Valenti M; Necozione S; Di Orio F
    J Urol (Paris); 1993; 99(6):283-7. PubMed ID: 7516367
    [No Abstract]   [Full Text] [Related]  

  • 40. Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level.
    Punglia RS; D'Amico AV; Catalona WJ; Roehl KA; Kuntz KM
    Cancer; 2006 Apr; 106(7):1507-13. PubMed ID: 16518812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.